RZLT / Rezolute, Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

A Late - stage Rare Disease Company Treating Hyperinsulinism Corporate Presentation NASDAQ: RZLT

Exhibit 99.2 A Late - stage Rare Disease Company Treating Hyperinsulinism Corporate Presentation NASDAQ: RZLT Forward Looking Statements | 2 This presentation, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward - looking statements regarding our prospective performance and strategies within the meaning of Section 27 A of the Sec

Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism Open-label study in as few as 16 tumor hyperinsulinism (HI) patients Study initiated and enrolling patients in the U.S. and Eu

Exhibit 99.1 Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism Open-label study in as few as 16 tumor hyperinsulinism (HI) patients Study initiated and enrolling patients in the U.S. and Europe Topline data expected in the second half of 2026 REDWOOD CITY, Calif., September 2, 2025 - Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute”

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 2, 2025 REZOLUTE, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 2, 2025 REZOLUTE, INC.

Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetug

Exhibit 99.1 Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetug REDWOOD CITY, Calif., August 20, 2025 - Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caus

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 18, 2025 REZOLUTE, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 18, 2025 REZOLUTE, INC.

Baseline demographics and disease characteristics were consistent with published epidemiology for this population. The extent of disease burden underscores the inadequacy of current SOC options which have lacked innovation for nearly half a century a

Exhibit 99.1 Baseline demographics and disease characteristics were consistent with published epidemiology for this population. The extent of disease burden underscores the inadequacy of current SOC options which have lacked innovation for nearly half a century and highlights the substantial unmet need in the congenital HI population. Notably, the magnitude of baseline hypoglycemia events and time

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 15, 2025 REZOLUTE, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 15, 2025 REZOLUTE, INC.

As filed with the Securities and Exchange Commission on July 17, 2025

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 17, 2025 Registration No.

SECURITIES PURCHASE AGREEMENT

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made as of , by and among Rezolute, Inc., a Nevada corporation (the “Company”), and each of those persons and entities, severally and not jointly, identified as a Purchaser on the Schedule of Purchasers attached as Exhibit A hereto (the “Schedule of Purchasers”). Such persons and entities together w

Calculation of Filing Fee Tables Form S-3 (Form Type) Rezolute, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Rezolute, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 13, 2025 REZOLUTE, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 13, 2025 REZOLUTE, INC.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No.

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025 U.S. Food and Drug Administ

Exhibit 99.1 Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025 U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation to ersodetug for hypoglycemia due to tumor hyperinsulinism REDWOOD CITY, Calif., May

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39683 REZO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2025 REZOLUTE, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2025 REZOLUTE, INC.

Rezolute, Inc. Announces Closing of Underwritten Offering

Exhibit 99.1 Rezolute, Inc. Announces Closing of Underwritten Offering NEW YORK—(BUSINESS WIRE)—April 25, 2025— Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the closing of its previously announced underwritten offering (the “Offering”) of an aggr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 25, 2025 REZOLUTE, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 25, 2025 REZOLUTE, INC.

Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”) Independent Data Monitoring Committee (the “DMC”) recommends continuation of sunRIZE trial as pla

Exhibit 99.1 Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”) Independent Data Monitoring Committee (the “DMC”) recommends continuation of sunRIZE trial as planned with no need to increase sample size Enrollment on track and expected to be completed in May 2025; topline data anticipated in Decem

       Shares of Common Stock and Pre-Funded Warrants to Purchase up to        Shares of Common Stock

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.

20,786,923 Shares of Common Stock and Pre-Funded Warrants to Purchase up to 6,905,385 Shares of Common Stock

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-275562 PROSPECTUS SUPPLEMENT (To Prospectus dated November 29, 2023) 20,786,923 Shares of Common Stock and Pre-Funded Warrants to Purchase up to 6,905,385 Shares of Common Stock We are offering 20,786,923 shares of our common stock, par value $0.001 per share (“common stock”) and in lieu of common stock to certain investors

Form of Pre-Funded Warrant

Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Rezolute, Inc., a Nevada corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the “Holder”), is entitled, subject to the terms set forth below, to pu

Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

Exhibit 99.1 Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants NEW YORK—(BUSINESS WIRE)—April 23, 2025— Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the pricing of an underwritten offering, priced at-th

Underwriting Agreement, dated as of April 23, 2025, by and between the Company and Guggenheim Securities, LLC

Exhibit 1.1 Execution Version 20,786,923 Shares of Common Stock and Pre-Funded Warrants to Purchase 6,905,385 Shares of Common Stock Rezolute, Inc. UNDERWRITING AGREEMENT April 23, 2025 Guggenheim Securities, LLC As Representative of the Several Underwriters Guggenheim Securities, LLC 330 Madison Avenue New York, NY 10017 Ladies and Gentlemen: Introductory. Rezolute, Inc., a Nevada corporation (th

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 23, 2025 REZOLUTE, INC.

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 23, 2025 REZOLUTE, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 25, 2025 REZOLUTE, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 25, 2025 REZOLUTE, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 12, 2025 REZOLUTE, INC.

Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and Orphan Drug Design

Exhibit 99.1 Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and Orphan Drug Designation Open-label arm (infant participants < 1 year old) of the sunRIZE study has been reviewed by a Data Monitoring Committee (DMC); targ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39683 R

Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism Open-label arm (infant participants < 1 year old) has been recently reviewed by a Data Monitoring Committee (DMC) a

Exhibit 99.1 Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism Open-label arm (infant participants < 1 year old) has been recently reviewed by a Data Monitoring Committee (DMC) and target drug concentrations were safely reached at tested doses DMC approved enrollment of infants into the double-blind portion of the

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2025 REZOLUTE, INC.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2025 REZOLUTE, INC.

Rezolute Film Transcript

Exhibit 99.1 Rezolute Film Transcript Ersodetug is an investigational drug candidate. The FDA has not determined that ersodetug is safe or effective. No indication(s), warnings, precautions, adverse reactions, dosage or administration information for ersodetug have been approved by the FDA. This video depicts the favorable results of ersodetug use for a single patient. It is not intended to guaran

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 7, 2025 REZOLUTE, INC.

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and curren

Exhibit 99.1 Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism (HI) Ersodetug continues to advance in clinical development as a potential treatment f

As filed with the Securities and Exchange Commission on December 30, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Rezolute, Inc. (Exact name of registran

Registration No. 333- As filed with the Securities and Exchange Commission on December 30, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Rezolute, Inc. (Exact name of registrant as specified in its charter) Nevada 27-3440894 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer

Form of Award Agreement for Inducement Award Outside of 2021 Equity Incentive Plan.*

Exhibit 99.1 Stock Option Agreement This Stock Option Agreement (this “Agreement”) is made and entered into as of [DATE] by and between Rezolute, Inc., a Nevada corporation (the “Company”) and [EMPLOYEE NAME] (the “Participant”). Grant Date: Exercise Price per Share: Number of Option Shares: Expiration Date: 1.            Grant of Option. 1.1            Grant; Type of Option. The Company hereby gr

Filing Fee Table *

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Rezolute, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 5, 2024 REZOLUTE, INC.

Certificate of Amendment, as filed with the Secretary of State of the State of Nevada on December 6, 2024 (incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K filed on December 10, 2024).

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED ARTICLES OF INCORPORATION OF REZOLUTE, INC. Rezolute, Inc. (the “Corporation”), a Corporation duly organized and existing under the Nevada Revised Statutes (the “NRS”), does hereby certify: FIRST: The amendment to the Corporation’s Amended and Restated Articles of Incorporation, set forth below, was duly adopted by written consent of

RZLT / Rezolute, Inc. / FIRST MANHATTAN CO Passive Investment

SC 13G/A 1 firstmanhattan-rzlt093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Rezolute, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 76200L309 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check t

RZLT / Rezolute, Inc. / Vivo Opportunity Fund Holdings, L.P. - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment

SC 13G/A 1 ea022116105-13ga2vivorezolu.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Rezolute, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 76200L309 (CUSIP Number) SEPTEMBER 30, 2024 (Date of Event which Require

RZLT / Rezolute, Inc. / Stonepine Capital Management, LLC Passive Investment

SC 13G/A 1 rzlt13ga4.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Rezolute, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 76200L309 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

RZLT / Rezolute, Inc. / Adage Capital Management, L.P. - REZOLUTE, INC. Passive Investment

SC 13G/A 1 p24-3077sc13ga.htm REZOLUTE, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)*, ** Rezolute, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 76200L309 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the app

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

EX-99.1 2 p24-3077exhibit991.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2024 REZOLUTE, INC.

Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), advancing in two late-stage, registrational clinical trials in tw

Exhibit 99.1 Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), advancing in two late-stage, registrational clinical trials in two indications Phase 3 sunRIZE study on track; U.S. enrollment expected to commence in the first part of 2025 Phase 3 tumor HI study expec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39683

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy

Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in the U.S. Phase 3 study for

Exhibit 99.1 Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in the U.S. Phase 3 study for ersodetug for the treatment of tumor HI expected to commence in the first half of 2025 REDWOOD CITY, Calif., September 19, 2024 – Rezolut

Form of Securities Purchase Agreement, dated June 25, 2024, by and between Rezolute, Inc., and the purchasers identified therein*

SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made as of June 27, 2024, by and among Rezolute, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 19, 2024 REZOLUTE, INC.

Employment Agreement of Daron Evans, dated September 15, 2024*

EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of September 18, 2024 (the “Effective Date”) by and between Daron Evans, (“Employee”), and Rezolute, Inc.

Exhibit 4.1

EXHBIT 4.1 DESCRIPTION OF SECURITIES General The following description summarizes the most important terms of our capital stock. It is subject to and qualified in its entirety by reference to our Amended and Restated Articles of Incorporation, as amended (“Articles of Incorporation”) and Amended and Restated Bylaws (“Bylaws”), which are included as exhibits to our annual report on Form 10-K, of wh

Clawback Policy*

Exhibit 97 REZOLUTE, INC. INCENTIVE COMPENSATION RECOVERY POLICY 1.Introduction. The Board of Directors of Rezolute, Inc., a Nevada corporation (the “Corporation”) believes that it is in the best interests of the Corporation and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Corporation's compensation philosophy. The Board has

Registration Rights Agreement, dated June 25, 2024, by and between Rezolute, Inc., and the purchasers identified therein*

REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of June , 2024 between Rezolute, Inc.

Listing of Subsidiaries

Exhibit 21.1 Subsidiaries of the Registrant Name of Entity Formation Date Jurisdiction of Incorporation Holder of Stock Rezolute Bio UK, Ltd July 11, 2019 United Kingdom Rezolute, Inc. Rezolute (Bio) Ireland Limited July 19, 2019 Ireland Rezolute, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-39683 REZO

FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study Commencing study startup activities in the U.S.; participant enrollment anticipated in early 2025

Exhibit 99.1 FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study Commencing study startup activities in the U.S.; participant enrollment anticipated in early 2025 REDWOOD CITY, Calif., September 9, 2024 – Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company develop

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 9, 2024 REZOLUTE, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 9, 2024 REZOLUTE, INC.

Rezolute, Inc. 275 Shoreline Drive, Suite 500 Redwood City, CA 94065

Rezolute, Inc. 275 Shoreline Drive, Suite 500 Redwood City, CA 94065 August 13, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Rezolute, Inc. (the "Company") Registration Statement on Form S-3/A File No. 333-281257 Ladies and Gentlemen: In accordance with Rules 460 and 461 under the Securities Act of 1933, as amended

As filed with the Securities and Exchange Commission on August 9, 2024

As filed with the Securities and Exchange Commission on August 9, 2024 Registration No.

Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism Second rare disease program with RZ358 in Phase 3 development Follows successful treatment of mul

Exhibit 99.1 Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism Second rare disease program with RZ358 in Phase 3 development Follows successful treatment of multiple patients with tumor hyperinsulinism under the Company’s Expanded Access Program REDWOOD CITY, Calif., August 5, 2024 – Rezolute, In

Forward Looking Statements | 2 This presentation, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within

Exhibit 99.2 Late-stage Rare Disease Company Treating Hyperinsulinism Corporate Presentation NASDAQ: RZLT Forward Looking Statements | 2 This presentation, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities

As filed with the Securities and Exchange Commission on August 5, 2024

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 5, 2024 Registration No.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 5, 2024 REZOLUTE, INC.

Filing Fee Table filed herewith as EX-FILING FEES

EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Rezolute, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit(1) Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration

Form of Securities Purchase Agreement dated June 25, 2024 by and between the Company and the Purchasers thereto

Exhibit 2.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made as of June 27, 2024, by and among Rezolute, Inc., a Nevada corporation (the “Company”), and each of those persons and entities, severally and not jointly, identified as a Purchaser on the Schedule of Purchasers attached as Exhibit A hereto (the “Schedule of Purchasers”). Such persons and entitie

Financial Statements and Exhibits, Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 28, 2024 REZOLUTE, INC.

Topline Results: RZ402 - 201 Phase 2 Study in Patients with Diabetic Macular Edema (DME) May 21, 2024

Exhibit 99.1 Topline Results: RZ402 - 201 Phase 2 Study in Patients with Diabetic Macular Edema (DME) May 21, 2024 This presentation, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward - looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 25, 2024 REZOLUTE, INC.

Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement Additional $6.7M in funding resulting in approximately $67M in gross proceeds

Exhibit 99.1 Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement Additional $6.7M in funding resulting in approximately $67M in gross proceeds NEW YORK-(BUSINESS WIRE)-Jun. 27, 2024- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapie

Underwriting Agreement, dated as of June 13, 2024, by and between the Company and Jefferies LLC and Cantor Fitzgerald & Co.

Exhibit 1.1 11,250,000 Shares of Common Stock and Pre-Funded Warrants to Purchase 3,750,000 Shares of Common Stock Rezolute, Inc. UNDERWRITING AGREEMENT June 13, 2024 JEFFERIES LLC CANTOR FITZGERALD & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o CANTOR FITZGERALD & CO. 110 E. 59th Street, 6th Floor New York, New York 10022 Lad

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 13, 2024 REZOLUTE, INC.

Form of Pre-Funded Warrant

Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Rezolute, Inc., a Nevada corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the “Holder”), is entitled, subject to the terms set forth below, to pu

Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants

Exhibit 99.1 Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants NEW YORK-(BUSINESS WIRE)-Jun. 13, 2024- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the pricing of its previously announced underwr

11,250,000 Shares of Common Stock and 3,750,000 Pre-Funded Warrants to Purchase Shares of Common Stock

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-275562 PROSPECTUS SUPPLEMENT (To Prospectus dated November 29, 2023)           11,250,000 Shares of Common Stock and 3,750,000 Pre-Funded Warrants to Purchase Shares of Common Stock We are offering 11,250,000 shares of our common stock, par value $0.001 per share (“common stock”) and in lieu of common stock to certain invest

Shares of Common Stock and Pre-Funded Warrants to Purchase Shares of Common Stock

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) Met primary study endpoints: good safety profile and reduction in central subfield thickness (CST) First oral therapy

Exhibit 99.1 Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) Met primary study endpoints: good safety profile and reduction in central subfield thickness (CST) First oral therapy to demonstrate reduction in macular edema; supports potential for early disease intervention Virtual investor event to be held today at

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2024 REZOLUTE, INC.

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 16, 2024 REZOLUTE, INC.

Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update Patient enrollment underway in sunRIZE global Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism (cHI); topline results expected in mid

Exhibit 99.1 Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update Patient enrollment underway in sunRIZE global Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Completed in-vivo toxicology study in brown Norway rats; early results show no abnormalities at highest tested dose of RZ358 Contin

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2024 REZOLUTE, INC.

Amended and Restated Form of Exchange Warrant

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39683 REZO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 23, 2024 REZOLUTE, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 23, 2024 REZOLUTE, INC.

Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting

Exhibit 99.1 Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting REDWOOD CITY, Calif., April 23, 2024 – Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that a poster titled “An Ana

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy

Form of Exchange Warrant

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Letter from Plante & Moran, PLLC, dated March 14, 2024

Exhibit 16.1 March 14, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01(a) of Form 8-K of Rezolute, Inc. dated March 14, 2024, and agree with the statements concerning our firm contained therein. We have no basis to agree or disagree with other statements of the registrant contained therein. Very truly yours, /s/ Plante & Moran,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 8, 2024 REZOLUTE, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 8, 2024 REZOLUTE, INC.

Form of Securities Exchange Agreement

Exhibit 10.1 SECURITIES EXCHANGE AGREEMENT THIS SECURITIES EXCHANGE AGREEMENT (this “Agreement”), is dated as of March 8, 2024 (the “Effective Date”), between Rezolute, Inc., a Nevada corporation, (the “Company”) and the subscriber (the “Subscriber”) are executing and delivering this Agreement in reliance upon an exemption from securities registration afforded by the provisions of Section 3(a)(9),

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 6, 2024 REZOLUTE, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 6, 2024 REZOLUTE, INC.

RZLT / Rezolute, Inc. / Nantahala Capital Management, LLC - SC 13G Passive Investment

SC 13G 1 tm248393d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* REZOLUTE, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 76200L309 (CUSIP Number) February 29, 2024 (Date of Event which Requires Filing of this Statement) Check the approp

March 6, 2024

Exhibit 99.1 March 6, 2024 Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH) Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism) REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT) (“Rezolu

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 21, 2024 REZOLUTE, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 13, 2024 REZOLUTE, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39683 R

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit shown in individual patient case

Exhibit 99.1 Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit shown in individual patient cases with RZ358 for tumor-associated hyperinsulinism (taHI) under Expanded Access Program (EAP); drives alignment with FDA on unmet need and

RZLT / Rezolute, Inc. / Vivo Opportunity Fund Holdings, L.P. - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment

SC 13G/A 1 ea193546-13ga1vivorezolute.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Rezolute, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 76200L309 (CUSIP Number) December 31, 2023 (Date of Event which Requires

RZLT / Rezolute, Inc. / Stonepine Capital Management, LLC Passive Investment

SC 13G/A 1 rzlt13ga2024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Rezolute, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 76200L309 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate b

RZLT / Rezolute, Inc. / FIRST MANHATTAN CO Passive Investment

SC 13G/A 1 firstmanhattan-rzlt123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Rezolute, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 76200L309 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check th

Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Exhibit 99.1 Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism REDWOOD CITY, Calif., January 23, 2024 - Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metaboli

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 23, 2024 REZOLUTE, INC.

Offer Letter for Daron Evans, dated January 23, 2024 (Incorporated by reference to Exhibit 10.1 of the Company’s Form 8-K filed on January 29, 2024)

Exhibit 10.1 January 23, 2024 VIA EMAIL: Dear Daron: We are very excited to offer you the position of Chief Financial Officer, at Rezolute, Inc., a Nevada corporation (“Company”). If you accept this offer, your first day of employment will be today, January 23, 2024 (“Effective Date”) and you will report to Nevan Elam, Chief Executive Officer. Additional terms of your employment are more fully des

Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

Exhibit 99.2 Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer REDWOOD CITY, Calif., January 24, 2024 - Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the addition of Daron Evans, MS, MBA, to its leadership t

RZLT / Rezolute, Inc. / FEDERATED HERMES, INC. Passive Investment

SC 13G/A 1 rzlt1576-form.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5*) REZOLUTE, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 76200L309 (CUSIP Number) December 31, 2023 (Date of Event Which R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 13, 2023 REZOLUTE, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 13, 2023 REZOLUTE, INC.

Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”) Plans to report topline data mid-second quarter 2024

Exhibit 99.1 Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”) Plans to report topline data mid-second quarter 2024 Redwood City, Calif., December 13, 2023 - Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the completion of en

Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism

Exhibit 99.2 Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism Company anticipates completing enrollment by the end of 2024 and reporting topline results in mid-year 2025 Redwood City, Calif., December 14, 2023 - Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and

Rezolute, Inc. 275 Shoreline Drive, Suite 500 Redwood City, CA 94065

Rezolute, Inc. 275 Shoreline Drive, Suite 500 Redwood City, CA 94065 November 27, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Rezolute, Inc. (the "Company") Registration Statement on Form S-3/A File No. 333-275562 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the u

As filed with the Securities and Exchange Commission on November 22, 2023

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 22, 2023 Registration No.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 21, 2023 REZOLUTE, INC.

Open Market Sale Agreement by and between Rezolute, Inc. and Jefferies, LLC

Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM November 14, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Rezolute, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, pa

As filed with the Securities and Exchange Commission on November 14, 2023

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 14, 2023 Registration No.

Form of Indenture.

Exhibit 4.6 REZOLUTE, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of , 20 Debt Securities Table of Contents Page article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Section 2.03 Den

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Rezolute, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title (1) Fee Calculation or Carry Forward Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit(3) Proposed Maximum Aggregate Offering Price(4) Fee Rate Amount of Reg

Rezolute Reports First Quarter Fiscal 2024 Results

Exhibit 99.1 Rezolute Reports First Quarter Fiscal 2024 Results Redwood City, Calif., November 13, 2023 - Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial results for the first quarter of fiscal 2024 ended September 30, 2023. “We are on track to co

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2023 REZOLUTE, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39683

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 17, 2023 REZOLUTE, INC.

Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and cur

Exhibit 99 Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism Redwood City, Calif.

RZLT / Rezolute Inc / Vivo Opportunity Fund Holdings, L.P. - SCHEDULE 13G Passive Investment

SC 13G 1 ea186730-13gvivorezolute.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Rezolute, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 76200L309 (CUSIP Number) October 5, 2023 (Date of Event which Requires Filing of this Statement) Che

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 11, 2023 REZOLUTE, INC.

Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism

Exhibit 99 Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism Redwood City, Calif.

Joint Filing Statement

EX-99.1 2 ea186730ex99-1rezolute.htm JOINT FILING STATEMENT EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filin

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 14, 2023 REZOLUTE, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-39683 REZO

Description of Securities

EXHBIT 4.1 DESCRIPTION OF SECURITIES General The following description summarizes the most important terms of our capital stock. It is subject to and qualified in its entirety by reference to our Amended and Restated Articles of Incorporation, as amended (“Articles of Incorporation”) and Amended and Restated Bylaws (“Bylaws”), which are included as exhibits to our annual report on Form 10-K, of wh

Listing of Subsidiaries

Exhibit 21.1 Subsidiaries of the Registrant Name of Entity Formation Date Jurisdiction of Incorporation Holder of Stock Rezolute Bio UK, Ltd July 11, 2019 United Kingdom Rezolute, Inc. Rezolute (Bio) Ireland Limited July 19, 2019 Ireland Rezolute, Inc.

Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023

Exhibit 99.1 Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023 REDWOOD CITY, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt treatm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 27, 2023 REZOLUTE, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 27, 2023 REZOLUTE, INC.

Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism Study to be initiated in Europe and other ex-US geographies in Q4 2023, with topline results expected 1H 2025 Conference c

Exhibit 99.1 Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism Study to be initiated in Europe and other ex-US geographies in Q4 2023, with topline results expected 1H 2025 Conference call scheduled today at 4:30 p.m. ET REDWOOD CITY, Calif., June 27, 2023 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT), a clinical-stag

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2023 REZOLUTE, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2023 REZOLUTE, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 30, 2023 REZOLUTE, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 30, 2023 REZOLUTE, INC.

Rezolute, Inc. Code of Ethics, as amended and restated as of May 30, 2023 (incorporated by reference to Exhibit 14.1 of the Company’s Form 8-K filed on June 2, 2023)

Exhibit 14.1 REZOLUTE, INC. CODE OF BUSINESS CONDUCT AND ETHICS The Board of Directors (the “Board”) of Rezolute, Inc. (the “Company”) adopted this Code of Business Conduct and Ethics (the “Code”) on May 30, 2023 and last updated this Code on December 31, 2017. The Board will periodically review this Code of Business Conduct and Ethics to ensure that it is adequate and up-to-date. This Code is int

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 25, 2023 REZOLUTE, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 25, 2023 REZOLUTE, INC.

Amended and Restated Employment Agreement of Brian Roberts, dated January 8, 2023 (incorporated by reference to Exhibit 10.2 of the Company’s Form 10-Q filed on May 11, 2023)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of January 8, 2023 (the “Effective Date”) by and between Brian Roberts, (“Employee”), and Rezolute, Inc.

Amended and Restated Employment Agreement of Nevan Elam, dated January 8, 2023 (incorporated by reference to Exhibit 10.1 of the Company’s Form 10-Q filed on May 11, 2023)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into effective as of January 8, 2023 (the “Effective Date”) by and between Rezolute, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39683 REZO

Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023

Exhibit 99.1 Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023 REDWOOD CITY, Calif., May 11, 2023 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2023 REZOLUTE, INC.

RZLT / Rezolute Inc / Genexine Inc. Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy

RZLT / Rezolute Inc / FIRST MANHATTAN CO Passive Investment

SC 13G 1 firstmanhattan-rzlt123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Rezolute, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 76200L309 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appro

RZLT / Rezolute Inc / CAXTON CORP Passive Investment

SC 13G/A 1 d993953313g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Rezolute, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 76200L309 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo

RZLT / Rezolute Inc / Stonepine Capital Management, LLC Passive Investment

SC 13G/A 1 rzlt13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Rezolute, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 76200L309 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t

Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress Initiated Phase 2 proof-of-concept study of RZ402 Anticipate initiation of global Phase 3 clinical study for RZ358 in mid 2023

Exhibit 99.1 Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress Initiated Phase 2 proof-of-concept study of RZ402 Anticipate initiation of global Phase 3 clinical study for RZ358 in mid 2023 REDWOOD CITY, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapie

Amended and Restated Employment Agreement of Brian Roberts, dated January 8, 2023

AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of January 8, 2023 (the “Effective Date”) by and between Brian Roberts, (“Employee”), and Rezolute, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2023 REZOLUTE, INC.

Amended and Restated Employment Agreement of Nevan Elam, dated January 8, 2023

AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into effective as of January 8, 2023 (the “Effective Date”) by and between Rezolute, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39683 R

RZLT / Rezolute Inc / FEDERATED HERMES, INC. Passive Investment

SC 13G/A 1 form828.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4*) REZOLUTE, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 76200L309 (CUSIP Number) December 31, 2022 (Date of Event Which Require

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2023 REZOLUTE, INC.

Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema

Exhibit 99.1 Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye REDWOOD CITY, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative th

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 15, 2022 REZOLUTE, INC.

Rezolute, Inc. Condensed Consolidated Financial Statements Data (in thousands, except per share data)

Exhibit 99.1 Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress Phase 2 proof-of-concept study of RZ402 expected to be initiated by the end of this year REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39683

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2022 REZOLUTE, INC.

Rezolute, Inc. 2022 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 4.2 of the Registration Statement on Form S-8 filed on November 7, 2022)

Exhibit 4.2 REZOLUTE, INC. 2022 EMPLOYEE STOCK PURCHASE PLAN (As Adopted June 16, 2022) 1.             General. (a)            Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock through accumulated payroll deductions. The Company’s intention is to have the Plan and Offerings thereunder qualify as an “

Rezolute, Inc. 201 Redwood Shores Parkway, Suite 315 Redwood City, CA 94065

CORRESP 1 filename1.htm Rezolute, Inc. 201 Redwood Shores Parkway, Suite 315 Redwood City, CA 94065 November 7, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Jimmy McNamara Re: Rezolute, Inc. Registration Statement on Form S-3 File No. 333-268046 Ladies and Gentlemen: In accordance with Rule 461 under the Securiti

As filed with the Securities and Exchange Commission on November 7, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Rezolute, Inc. (Exact name of registrant

Registration No. 333- As filed with the Securities and Exchange Commission on November 7, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Rezolute, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 27-3440894 (I.R.S. Employer

Filing Fee Table *

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Rezolute, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $

As filed with the Securities and Exchange Commission on October 28, 2022

As filed with the Securities and Exchange Commission on October 28, 2022 Registration No.

Filing Fee Table filed herewith as EX-FILING FEES

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Rezolute, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 15, 2022 REZOLUTE, INC.

Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress Announced a $130 million registered direct offering and concurrent private placement priced at-the-market Late-breaking oral presentation from Phase 2b

Exhibit 99.1 Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress Announced a $130 million registered direct offering and concurrent private placement priced at-the-market Late-breaking oral presentation from Phase 2b RIZE study of RZ358 presented at ESPE 2022 Phase 2 proof-of-concept study of RZ402 expected to be initiated later this year REDWOOD CITY,

Listing of Subsidiaries

Exhibit 21.1 Subsidiaries of the Registrant Name of Entity Formation Date Jurisdiction of Incorporation Holder of Stock Rezolute Bio UK, Ltd July 11, 2019 United Kingdom Rezolute, Inc. Rezolute (Bio) Ireland Limited July 19, 2019 Ireland Rezolute, Inc. ?

Rezolute, Inc. Amended and Restated 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.23 of the Company’s Form 10-K filed on September 15, 2022)

? Exhibit 10.23 ? REZOLUTE, INC. 2021 EQUITY INCENTIVE PLAN (as amended and restated on June 16, 2022) Section 1. Purpose The purpose of the Plan is to promote the interests of the Company and its shareholders by aiding the Company in attracting and retaining employees, officers, consultants, advisors and non-employee Directors capable of assuring the future success of the Company, to offer such p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Form of Amended and Restated Securities Purchase Agreement, dated as of July 22, 2022 (incorporated by reference to Exhibit 10.22 of the Company’s Form 10-K filed on September 15, 2022)

? Exhibit 10.22 ? AMENDED AND RESTATED SECURITIES PURCHASE AGREEMENT Rezolute, Inc. 201 Redwood Shores Parkway, Suite 315 Redwood City, California 94065 Ladies and Gentlemen: The undersigned (the ?Investor?) hereby confirms its agreement with you as follows: 1.This Subscription Agreement (this ?Agreement?) is made as of the date set forth below between Rezolute, Inc., a Nevada corporation (the ?Co

Termination of a Material Definitive Agreement, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 30, 2022 REZOLUTE, INC.

Up to 10,947,371 Shares of Common Stock Issuable upon Conversion of Warrants

Filed Pursuant to 424(b)(3) Registration No. 333-265703 PROSPECTUS Up to 10,947,371 Shares of Common Stock Issuable upon Conversion of Warrants This prospectus relates to the resale of 10,947,371 shares of Common Stock, par value $0.001 per share (?Common Stock?) of Rezolute, Inc. (the ?Company?) by Federated Hermes Kaufmann Small Cap Fund, Federated Hermes Kaufmann Fund, Federated Hermes Kaufmann

Rezolute, Inc. 201 Redwood Shores Parkway, Suite 315 Redwood City, CA 94065

Rezolute, Inc. 201 Redwood Shores Parkway, Suite 315 Redwood City, CA 94065 June 29, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Jane Park Re: Rezolute, Inc. Registration Statement on Form S-3 File No. 333-265703 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the

As filed with the Securities and Exchange Commission on June 28, 2022

As filed with the Securities and Exchange Commission on June 28, 2022 Registration No.

RZLT / Rezolute Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. - REZOLUTE, INC. Passive Investment

SC 13G 1 p22-1735sc13g.htm REZOLUTE, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Rezolute Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 76200L309 (CUSIP Number) June 16, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to

Certificate of Amendment as filed with the Nevada Secretary of State of the State of Nevada filed on June 16, 2022

Exhibit 3.1 ARTICLES OF AMENDMENT TO THE ARTICLES OF INCORPORATION OF REZOLUTE, INC. Rezolute, Inc. (the ?Corporation?), a Corporation duly organized and existing under the Nevada Revised Statutes (the ?NRS?), does hereby certify: FIRST: The amendment to the Corporation?s Articles of Incorporation, set forth below, was duly adopted by written consent of the Board of Directors of the Corporation on

As filed with the Securities and Exchange Commission on June 17, 2022

As filed with the Securities and Exchange Commission on June 17, 2022 Registration No.

Filing Fee Table filed herewith as EX-FILING FEES

Exhibit 107 FORM S-3 (Form Type) REZOLUTE, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2022 REZOLUTE, INC.

Common Stock

Filed pursuant to Rule 424(b)(5) Registration No. 333-251498 PROSPECTUS SUPPLEMENT (To prospectus dated June 23, 2021) Common Stock This prospectus supplement amends, supplements, and supersedes our prospectus supplement filed December 18, 2020, relating to an Equity Distribution Agreement (the ?Sales Agreement?) with Oppenheimer & Co. Inc., or Oppenheimer, in an at the market offering. The Sales

Shares of Common Stock

Filed pursuant to Rule 424(b)(5) Registration No. 333-251498 PROSPECTUS SUPPLEMENT (To prospectus dated June 23, 2021) Shares of Common Stock This prospectus supplement amends, supplements, and supersedes our prospectus supplement dated August 3, 2021, relating to a purchase agreement (the ?Purchase Agreement?) with Lincoln Park Capital Fund, LLC, or Lincoln Park. The Purchase Agreement provided f

Termination of a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 16, 2022 (May 10, 2022) REZOLUTE, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ?

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2022 REZOLUTE, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress Announced a $130 million registered direct offering and concurrent private placement Positive topline results from Phase 2b RIZE study of RZ358 exceeded expe

Exhibit 99.1 Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress Announced a $130 million registered direct offering and concurrent private placement Positive topline results from Phase 2b RIZE study of RZ358 exceeded expectations and demonstrated highly significant reduction in hypoglycemia events, ~75% at anticipated therapeutic doses Positive data from P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ?

Form of Class C Warrant

Exhibit 4.3 THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAI

Securities Purchase Agreement, dated as of May 1, 2022, by and between the Company and the purchasers identified therein

Exhibit 10.3 Execution Version SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this ?Agreement?) is made as of May 1, 2022 by and among Rezolute, Inc., a Nevada corporation (the ?Company?), and each of those persons and entities, severally and not jointly, identified as a Purchaser on the Schedule of Purchasers attached as Exhibit A hereto (the ?Schedule of Purchasers?). Such per

Registration Rights Agreement, dated as of May 4, 2022, by and between Rezolute, Inc., and the purchasers identified therein (incorporated by reference to Exhibit 10.1 of the Company’s Form 8-K filed on May 4, 2022)

Exhibit 10.1 FORM OF REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of May 4, 2022 between Rezolute, Inc., a Nevada corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the Underwriting Agreement, d

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2022 (May 1, 2022) REZOLUTE, INC.

Form of Class B Pre-Funded Warrant (incorporated by reference to Exhibit 4.2 of the Company’s Form 8-K filed on May 4, 2022)

Exhibit 4.2 FORM OF CLASS B PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: May 4, 2022 Rezolute, Inc., a Nevada corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the ?Holder?), is entitled, su

Rezolute, Inc. Announces Closing of Registered Direct Offering

Exhibit 99.1 Rezolute, Inc. Announces Closing of Registered Direct Offering REDWOOD CITY, Calif., May 4, 2022 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced the closing of its previously announce

Form of Class C Registration Rights Agreement, dated as of May 1, 2022, by and between the Company the purchasers identified therein

Exhibit 10.4 Execution Version FORM OF REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of May 1, 2022 between Rezolute, Inc., a Nevada corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the Securit

Underwriting Agreement, dated as of May 1, 2022, by and between the Company and Jefferies LLC (incorporated by reference to Exhibit 1.1 of the Company’s Form 8-K filed on May 4, 2022)

Exhibit 1.1 Execution Version 18,026,315 Shares of Common Stock And Pre-Funded Warrants to Purchase 12,921,055 Shares of Common Stock Rezolute, Inc. UNDERWRITING AGREEMENT May 1, 2022 JEFFERIES LLC As Representative of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. Rezolute, Inc., a Nevada corporation (the ?Company?), prop

Form of Class A Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of the Company’s Form 8-K filed on May 4, 2022)

Exhibit 4.1 FORM OF CLASS A PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: May [ ], 2022 Rezolute, Inc., a Nevada corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the ?Holder?), is entitled,

Placement Agency Agreement, dated as of May 1, 2022, by and between the Company and Jefferies LLC (incorporated by reference to Exhibit 10.2 of the Company’s Form 8-K filed on May 4, 2022)

Exhibit 10.2 Execution Version 3,263,157 Class C Pre-Funded Warrants to Purchase Shares of Common Stock Rezolute, Inc. PLACEMENT AGENCY AGREEMENT May 1, 2022 JEFFERIES LLC 520 Madison Avenue, 12th Floor New York, New York 10022 Ladies and Gentlemen: Introductory. Rezolute, Inc., a Nevada corporation (the ?Company?), proposes to issue and sell to certain purchasers (collectively, the ?Purchasers?)

Corporate Deck Restoring Balance to Life with Transformative Therapies April 2022

Exhibit 99.3 Corporate Deck Restoring Balance to Life with Transformative Therapies April 2022 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward - looking statements relating to future events, and as such all forward - looking statements are made pursuant to the Securities Litigation Reform Act of 1995 . Statements may contain cert

18,026,315 Shares of Common Stock Class A Pre-Funded Warrants to Purchase up to 1,973,684 Shares of Common Stock 10,947,371 Class B Pre-Funded Warrants

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-251498 PROSPECTUS SUPPLEMENT (To Prospectus dated June 23, 2021) 18,026,315 Shares of Common Stock Class A Pre-Funded Warrants to Purchase up to 1,973,684 Shares of Common Stock 10,947,371 Class B Pre-Funded Warrants We are offering 18,026,315 shares of our common stock, par value $0.001 per share. In addition, in lieu of co

Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism Results Presented Today at the Pediatric Endocrine Society’s 2022 Annual Meeting

Exhibit 99.2 Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism Results Presented Today at the Pediatric Endocrine Society?s 2022 Annual Meeting ? Highly significant ~75% reduction in hypoglycemia events at anticipated therapeutic doses ? ?50% improvement in hypoglycemia in 100% of patients in high-dose cohort, with no adverse drug

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2022 (May 1, 2022) REZOLUTE, INC.

Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market

Exhibit 99.1 Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market REDWOOD CITY, Calif., May 1, 2022 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metaboli

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 29, 2022 REZOLUTE, INC.

Rezolute Joins the Rare Disease Company Coalition Rezolute joins group aimed at helping advance timely access to life-saving therapies for those impacted by rare diseases

Exhibit 99.1 Rezolute Joins the Rare Disease Company Coalition Rezolute joins group aimed at helping advance timely access to life-saving therapies for those impacted by rare diseases REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current

Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism --The RIZE study demonstrated highly significant improvements in hypoglycemia and good safety and tolerability Results to be presented in an oral

Exhibit 99.1 Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism -The RIZE study demonstrated highly significant improvements in hypoglycemia and good safety and tolerability Results to be presented in an oral presentation at a medical congress in 2Q 2022 REDWOOD CITY, Calif., March 23, 2022 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT), a cli

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2022 REZOLUTE, INC.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 22, 2022 REZOLUTE, INC.

Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME Phase 2 proof-of-concept study anticipated in 2H 2022

Exhibit 99.1 Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME Phase 2 proof-of-concept study anticipated in 2H 2022 REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announc

RZLT / Rezolute Inc / Stonepine Capital Management, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Rezolute, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 76200L309 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur

RZLT / Rezolute Inc / FEDERATED HERMES, INC. Passive Investment

OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3*) REZOLUTE, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 76200L309 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statem

RZLT / Rezolute Inc / CAXTON CORP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress Topline results from RZ358 Phase 2b and RZ402 Phase 1b studies expected before the end of Q1 2022

Exhibit 99.1 Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress Topline results from RZ358 Phase 2b and RZ402 Phase 1b studies expected before the end of Q1 2022 REDWOOD CITY, Calif., February 9, 2022 (GLOBE NEWSWIRE) ? Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases asso

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 9, 2022 REZOLUTE, INC.

RZLT / Rezolute Inc / Stonepine Capital Management, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Rezolute, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 76200L309 (CUSIP Number) December 21, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs

Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress

Exhibit 99.1 Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress REDWOOD CITY, Calif., November 12, 2021 (GLOBE NEWSWIRE) ? Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced its financial results for the first

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2021 REZOLUTE, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

RZLT / Rezolute Inc / FEDERATED HERMES, INC. Passive Investment

OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2*) REZOLUTE, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 76200L309 (CUSIP Number) October 31, 2021 (Date of Event Which Requires Filing of this Stateme

ABSTRACT FOR THE 2021 ASRS MEETING

Exhibit 99.1 ABSTRACT FOR THE 2021 ASRS MEETING Title: A Phase 1 Single Dose Study of RZ402: a Novel Orally Administered Plasma Kallikrein Inhibitor to Target Diabetic Macular Edema Presenters: Robert Bhisitkul, MD, PhD1, Quan Dong Nguyen, MD, MSc2, Brian Roberts, MD3, Rajat Agrawal, MD, MS3 1. Department of Ophthalmology, University of California, San Francisco, CA 2. Byers Eye Institute, Stanfor

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 19, 2021 (October 13, 2021) REZOLUTE, INC.

6,030,847 Shares of Common Stock Pre-Funded Warrants to Purchase up to 1,661,461 Shares of Common Stock

TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5) ?Registration No. 333-251498 ? ? PROSPECTUS SUPPLEMENT (To Prospectus dated June 23, 2021) 6,030,847 Shares of Common Stock Pre-Funded Warrants to Purchase up to 1,661,461 Shares of Common Stock We are offering 6,030,847 shares of our common stock, par value $0.001 per share. In addition, in lieu of common stock, we are also offering pre-funded w

769,231 Shares of Common Stock

TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5)? ?Registration No. 333-251498? PROSPECTUS SUPPLEMENT (To Prospectus dated June 23, 2021) 769,231 Shares of Common Stock We are offering shares of our common stock, par value $0.001 per share at a purchase price of $6.50 per share, pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is traded on The Nasdaq Capi

Underwriting Agreement, dated as of October 12, 2021, by and between the Company and Oppenheimer & Co., Inc. (incorporated by reference to Exhibit 1.1 of the Company's Form 8-K filed on October 13, 2021)

Exhibit 1.1 6,030,847 Shares of Common Stock Pre-Funded Warrants to Purchase 1,661,461 Shares of Common Stock Rezolute, Inc. UNDERWRITING AGREEMENT October 12, 2021 Oppenheimer & Co. Inc. as Representative of the several Underwriters named in Schedule I hereto 85 Broad Street New York, NY 10004 Ladies and Gentlemen: Rezolute, Inc., a Nevada corporation (the ?Company?), proposes, subject to the ter

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering

Exhibit 99.1 Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering REDWOOD CITY, Calif., October 12, 2021 (GLOBE NEWSWIRE) ? Rezolute, Inc. (Nasdaq: RZLT) (?Rezolute? or the ?Company?), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbal

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 13, 2021 (October 12, 2021) REZOLUTE, INC.

Form of Subscription Agreement, dated October 12, 2021 (incorporated by reference to Exhibit 10.1 of the Company’s Form 8-K filed on October 13, 2021)

Exhibit 10.1 FORM OF SUBSCRIPTION AGREEMENT Rezolute, Inc. 201 Redwood Shores Parkway, Suite 315 Redwood City, California 94065 Ladies and Gentlemen: The undersigned (the ?Investor?) hereby confirms its agreement with you as follows: 1. This Subscription Agreement (this ?Agreement?) is made as of the date set forth below between Rezolute, Inc., a Nevada corporation (the ?Company?), and the Investo

Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering

Exhibit 99.2 Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering REDWOOD CITY, Calif., October 13, 2021 (GLOBE NEWSWIRE) ? Rezolute, Inc. (Nasdaq: RZLT) (?Rezolute? or the ?Company?), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chroni

Form of Pre-Funded Warrant to Purchase Common Stock (Incorporated by reference to Exhibit 4.1 of the Company’s Form 8-K filed on October 13, 2021)

Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ], 2021 Rezolute, Inc., a Nevada corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the ?Holder?), is entitled, subject to t

Subject to completion, dated October 12, 2021

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Amendment No. 1) (Mark One) ? Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2021 ? Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from to Commission File Number 000-54495 REZO

Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021 Continuous glucose monitoring reveals undertreated hypoglycemia in patients with congenital hyperinsulinis

Exhibit 99.1 Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021 Continuous glucose monitoring reveals undertreated hypoglycemia in patients with congenital hyperinsulinism RZ358, a monoclonal antibody in Phase 2b development, has normalized blood glucose levels in prior studies REDWOOD CITY, Calif., Septem

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 23, 2021 (September 22, 2021) REZOLUTE, INC.

Amended and Restated Bylaws of Rezolute Nevada Merger Corporation (incorporated by reference to Exhibit 3.4 of the Company’s Form 10-K filed on September 15, 2021)

Exhibit 3.4 REZOLUTE, INC. AMENDED AND RESTATED BYLAWS (effective June 18, 2021) ARTICLE I - STOCKHOLDERS Section 1. Annual Meeting. An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Board o

Listing of Subsidiaries*

Exhibit 21.1 Subsidiaries of the Registrant Name of Entity Formation Date Jurisdiction of Incorporation Holder of Stock Rezolute Bio UK, Ltd July 11, 2019 United Kingdom Rezolute, Inc. Rezolute (Bio) Ireland Limited July 19, 2019 Ireland Rezolute, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2021 ? Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from to Commission File Number 000-54495 REZOLUTE, INC. (Exact

Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress

EX-99.1 2 tm2127730d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress REDWOOD CITY, Calif., September 15, 2021 (GLOBE NEWSWIRE) – Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose im

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 15, 2021 REZOLUTE, INC.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 13, 2021 (September 9, 2021) REZOLUTE, INC.

Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism Tracking to Announce Top line data in Q1 2022

EX-99.1 2 tm2127422d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism Tracking to Announce Top line data in Q1 2022 REDWOOD CITY, CA, September 9, 2021 (GLOBE NEWSWIRE) – Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for meta

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): ??August 10, 2021 REZOLUTE, INC.

Rezolute Announces initiation of multiple-ascending dose study of RZ402, Rezolute’s oral PKI for treatment of DME

Exhibit 99.1 Rezolute Announces initiation of multiple-ascending dose study of RZ402, Rezolute?s oral PKI for treatment of DME REDWOOD CITY, Calif., August 10, 2021 (GLOBE NEWSWIRE) ? Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced that the Company has ini

Up to $20,000,000 of Shares of Common Stock and 33,799 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-251498 PROSPECTUS SUPPLEMENT (To Prospectus dated June 23, 2021) Up to $20,000,000 of Shares of Common Stock and 33,799 Shares of Common Stock This prospectus supplement relates to the issuance and sale of up to $20,000,000 of shares of our common stock, or Purchase Shares, that we may sell to Lincoln Park Capital Fund, LLC, or Lincoln Park, fr

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2021 REZOLUTE, INC.

Registration Rights Agreement, dated as of August 2, 2021 by and between the Company and Lincoln Park Capital Fund, LLC

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of August 2, 2021, is entered into by and between REZOLUTE, INC., a Nevada corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the ?Investor?). Capitalized terms used herein and not otherwise defined here

Purchase Agreement, dated as of August 2, 2021 by and between the Company and Lincoln Park Capital Fund, LLC

Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the ?Agreement?), dated as of August 2, 2021, is made by and between REZOLUTE, INC., a Nevada corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the ?Investor?). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the In